Aimmune Therapeutics — Technical Presentation (February 2018)
13 slides from Aimmune Therapeutics's technical presentation, Feb 20, 2018
Slide 1: Phase 3 PALISADE Trial Top-Line Results
February 20, 2018 Phase 3 PALISADE Trial Top-Line Results Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, clinical development plans, anticipated milestones, product candidate benefits, potential market size, product adoption
Slide 3: Phase 3 PALISADE Trial of AR101: Topline Data Overview
Phase 3 PALISADE Trial of AR101: Topline Data Overview PALISADE (Peanut ALlergy Oral Immunotherapy Study of AR101 for DEsensitization) was an international, multicenter, randomized, double-blind, placebo-controlled, Phase 3 study of AR101 in peanut-allergic individuals PALISADE had 554 randomized pa
Slide 4: PALISADE Trial Design
PALISADE Trial Design DBPCFC = Double-Blind, Placebo-Controlled Food Challenge; conducted by independent, blinded assessors not involved in the patients’ care Tolerate = dose is successfully ingested with no more than mild symptoms
Slide 5: PALISADE Baseline Characteristics
PALISADE Baseline Characteristics Characteristics, n (%) AR101 patients (n=372) Placebo patients (n=124) Totals (n=496) Sex Male Female 208 (56%) 164 (44%) 76 (61%) 48 (39%) 284 (57%) 212 (43%) Age 4-11 years 12-17 years 238 (64%) 134 (36%) 89 (72%) 35 (28%) 327 (66%) 169 (34%) Baseline sensitivity
Slide 6: AR101 Met the Primary and Secondary Efficacy Endpoints in the PALISADE Trial
AR101 Met the Primary and Secondary Efficacy Endpoints in the PALISADE Trial ITT Analysis: Patients Ages 4-17 Who Tolerated Each Dose Level at Exit DBPCFC *p<0.00001 for Treatment Difference >15% ITT: Intent-to-Treat
Slide 7: AR101 PALISADE Completer Analysis
AR101 PALISADE Completer Analysis Completers: Patients Ages 4-17 Who Tolerated Each Dose Level at Exit DBPCFC *p<0.00001 for Treatment Difference >15% Completers: 79.6% of AR101-treated and 93.5% of placebo-treated patients were evaluable in the exit DBPCFC
Slide 8: Topline Safety and Tolerability Profile
Topline Safety and Tolerability Profile 496 patients ages 4-17 were evaluable for safety (372 AR101 and 124 placebo) The incidence of reported serious adverse events (SAEs) was low in both arms 9 patients in the AR101-treated arm (2.4%); of these, 5 patients experienced mild or moderate SAEs and 4 p
Slide 9: AR101 Discontinuations in Patients Ages 4-17
AR101 Discontinuations in Patients Ages 4-17 AR101 (n=372) % n Total discontinuations regardless of causality 20.4% 76 Discontinuations not related to adverse events 8.0% 30 Discontinuations related to adverse events 12.4% 46 Gastrointestinal1 6.7% 25 Systemic hypersensitivity reactions2 2.7% 10 Res
Slide 10: PALISADE Topline Efficacy Summary
PALISADE Topline Efficacy Summary Primary and Secondary Efficacy Analyses Completed in Accordance with Agreed Hierarchical Statistical Analysis Plan in Patients Ages 4-17 300 mg 600 mg 1000 mg AR101 (n=372) 76.6% 67.2% 50.3% Placebo (n=124) 8.1% 4.0% 2.4% 95% CI Difference (58.6–78.5%) (53.0–73.3%)
Slide 11: AR101 Path to Regulatory Submissions
AR101 Path to Regulatory Submissions Needed for BLA Submission Anticipated in late 2018 AR101 has U.S. FDA Breakthrough Therapy Designation for peanut-allergic patients ages 4–17 Needed for MAA Submission Anticipated in 1H 2019 PALISADE trial Late-breaker presentation at AAAAI on March 4 ARC004 (PAL
Slide 12: Appendix
Appendix 2 IO IOC Tr Tr
Slide 13: Understanding the Clinical Trial Endpoint: Tolerated Dose
Understanding the Clinical Trial Endpoint: Tolerated Dose The Double-Blind, Placebo-Controlled Food Challenge (DBPCFC) Is a Surrogate for Accidental Exposure *Deschildre A, et al.Clin Exp Allergy. 2016 Apr;46(4):610-20 Milligrams of Peanut Protein ENTRY React EXIT Tolerate 3 10 30 100 300 600 3 10 3
Aimmune Therapeutics — Technical Presentation (February 2018) on 6ix